Biotech, bite-sized — UK science, explained fast
The NHS heel-prick test and the newborn genomic research programme are not the same offer. Here is a plain-English question sheet for UK parents, plus notes for the lab staff who field the answers at 2am.
A research-use-only antibody can look like a bargain on the purchase order and a headache in the quality manual. Here is how UK labs can spot the moment a reagent stops being research kit and starts looking like a diagnostic.
Moving sequencing data into the cloud is usually a drag-and-drop. Defending it later is a paper trail. Here’s a plain-English walkthrough for UK genomics teams on DPAs, NHS residency expectations and the anonymisation caveats that catch people out.
A plasmid leaves the freezer long before legal signs off. This pre-shipment MTA walkthrough covers derivative ownership, publication wording, commercial-use traps and the university-versus-company delays that strand UK parcels.
A hypothetical CAR-T shipment from London to a regional NHS treatment centre shows why the signature at the loading bay is only the last step in a much longer evidence trail. Here is what pharmacists, QA teams and early-career biotech staff should ask before accepting a temperature-sensitive therapy in 2026.
A VUS can look alarming in a clinic letter and sound like a diagnosis in a corridor conversation. Here is a field-by-field guide to what an NHS genomic report is actually saying in 2026, and the questions that move the conversation from uncertainty to a plan.
That entry-level technician ad wants a PhD, five years of GMP, and a sense of humour? Here is how to tell which lines are trainable wishlist and which are genuine deal-breakers, plus a five-minute check before you lose a weekend to the application form.
When a UK biotech enters administration, the liquidator inherits more than benches and debtors — they inherit freezers, cloud tenancies and a tangle of data licences. Here is a practical ten-point audit for early-career scientists who want their work to survive the wind-down.
A validated biomarker assay can clear the bench and still stall before NHS patients see it. Here’s the documentation a UK lab should bank now — clinical utility, coding, capacity and cost — so the test survives NICE scrutiny and local commissioning in 2026.
Direct-to-consumer gut tests are now a checkout-aisle purchase in the UK, but the £90 kit in your basket and the £300 one on a specialist site are often answering completely different questions. Here's what happens between your sample and your results page — and where the two can disagree.
Cultivated meat is moving from lab demo to regulatory checklist. Here’s what the FSA’s 2026 authorisation route asks for, where labelling could get messy, and why the bioreactor—not the bun—is the real bottleneck.
Before a UK cell-or-gene therapy batch can reach a patient, a Qualified Person has to put their name to it. Here is what that signature actually covers, why small ATMP manufacturers feel the squeeze, and how early-career scientists can make release week less painful.
A catalogue number can get an antibody onto a purchase order, but it cannot tell you whether the band is real. This 2026 walkthrough gives UK students and lab managers a practical due-diligence routine for RRIDs, knockout controls, core-facility help and the questions worth asking before a vial earns freezer space or a figure panel.
Joining animal-based research as a UK student? The project licence is not background admin — it sets the limits on what can be done and by whom. This short checklist helps you ask better questions before your first protocol day.
When a gene-editing therapy moves from trial data into an NHS pathway, patients and carers need plainer answers than a press release can give. This audit sets out what MHRA authorisation, NICE appraisal and long-term follow-up actually mean, with a checklist for reading the next UK announcement.
A £50K benchtop sequencer can look like a bargain until the service contract, flow cells and storage bill arrive. This practical UK buying guide walks through the questions academic labs and early-stage biotech teams should ask before signing a three-year deal.
Most containment failures start as administrative gaps, not dramatic accidents. This short audit checks the notification, risk assessment, GM safety committee sign-off and waste trail before a CRISPR experiment begins.
Biobank consent forms are not paperwork to skim on the way to the freezer. This practical audit treats consent language like a protocol: version checks, permitted uses, withdrawal routes and the questions to settle before any human sample is thawed.
Bacteriophage therapy is moving from dramatic case reports into UK clinical studies, but the evidence base is still uneven. Here’s a plain-English guide to what phage therapy is, where UK research is happening, and how students can tell a promising trial from a compelling anecdote.
Biofoundries are the UK’s shared labs for synthetic biology, but access can feel mysterious. This practical guide profiles five facilities, explains how booking and training usually work, and suggests a beginner-friendly project for each.